IRADIMED CORPORATION reported strong financial results for the third quarter and nine months ended September 30, 2025.
Financial Performance: For the three months ended Q3 2025, Revenue increased 16% YoY to \(21.2 million, with Net Income supporting a Diluted EPS of \)0.43. For the nine months, Revenue reached \(61.12 million (up 13.5%) and Net Income was \)16.04 million, yielding a Diluted EPS of \(1.25. The balance sheet is strong, with Cash at \)56.5 million and significant asset growth (Total Assets up 16.7% to \(114.72M). Deferred Revenue increased to \)6.73M, indicating strong future commit
...